Evidence map›Paper›PMID 42477257›Full record

ArticleNeurocritical care2026

Patient-and Caregiver-Centered Outcomes in Survivors of Severe Stroke with Respiratory Failure at 6 Months: A Substudy of the SETPOINT2 Trial.

Matthew N Jaffa, David B Seder, Susanne Muehlschlegel, Jan Meis, David Y Hwang, Wolf-Dirk Niesen, Stefan Wolf, Nicholas A Morris, Jeremy T Ragland, Bryan Gough and 14 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Matthew N Jaffa *Division of Neurocritical Care, Department of Neurology, Ayer Neuroscience Institute, Hartford Hospital, Hartford, CT, USA. Matthew.jaffa@hhchealth.org.ORCID http://orcid.org/0000-0001-9123-4627
David B Seder *Department of Critical Care Services, Maine Medical Center, Portland, ME, USA.
Susanne MuehlschlegelDivision of Neurosciences Critical Care, Departments of Neurology, Anesthesiology & Critical Care Medicine, and Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jan MeisInstitute of Medical Biometry, University of Heidelberg, Heidelberg, Germany.
David Y HwangDivision of Neurocritical Care, Department of Neurology, The University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Wolf-Dirk NiesenDepartment of Neurology and Neuroscience, Medical Center-University of Freiburg, Freiburg, Germany.
Stefan WolfDepartment of Neurosurgery, Charité University Medicine Berlin, Berlin, Germany.
Nicholas A MorrisDepartment of Neurology, University of Maryland School of Medicine, Baltimore, MD, USA.
Jeremy T RaglandDepartment of Neurology, Wellstar Health System, Marietta, TX, USA.
Bryan GoughDepartment of Neurology, Ohio State University, Wexner Medical Center, Columbus, OH, USA.
Hauke SchneiderDepartment of Neurology, Augsburg University Hospital, Augsburg, Germany.
Jan-Oliver NeumannDepartment of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany.
Phani KantamneniDepartment of Medicine, Kadlec Regional Medical Center, Richland, WA, USA.
Michael L JamesDepartments of Anesthesiology and Neurology, Duke University Hospital, Durham, NC, USA.
William D FreemanDepartments of Neurology, Neurologic Surgery, and Critical Care, Mayo Clinic, Jacksonville, FL, USA.
Venkatakrishna RajajeeDepartment of Neurosurgery and Neurology, University of Michigan, Ann Arbor, MI, USA.
Chethan Venkatasubba RaoDepartment of Neurology, Neurosurgery and Center for Space Medicine, Baylor College of Medicine, Houston, TX, USA.
Deepak NairIllinois Neurological Institute, Peoria, IL, USA.
Laura KohlhasInstitute of Medical Biometry, University of Heidelberg, Heidelberg, Germany.
Christina KloseInstitute of Medical Biometry, University of Heidelberg, Heidelberg, Germany.
Meinhard KieserInstitute of Medical Biometry, University of Heidelberg, Heidelberg, Germany.
José I SuarezDivision of Neurosciences Critical Care, Departments of Neurology, Anesthesiology & Critical Care Medicine, and Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Silvia SchönenbergerDepartment of Neurology, Heidelberg University Hospital, Heidelberg, Germany.
Julian BöselDivision of Neurosciences Critical Care, Departments of Neurology, Anesthesiology & Critical Care Medicine, and Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

Patient-Centered Outcomes Research Institute CER 1602-34137
6 · The paper itself

Abstract

BACKGROUND/

objectiveThe multicenter trial SETPOINT2 comparing early versus delayed tracheostomy in severe stroke was conducted in Germany and the USA. A pre-specified aim was to assess 6-month patient- and caregiver-reported outcomes to better inform clinical decision-making in the acute phase of care, irrespective of tracheostomy timing.

methodsPatients had acute ischemic, hemorrhagic, or subarachnoid hemorrhage (SAH) strokes, respiratory failure, and a predicted necessity for tracheostomy (SETscore > 10). Outcome measures assessed by telephone interview 6 months after hospital admission included the modified Rankin scale (mRS), EuroQol 5D-5L (EQ-5D-5L), EuroQol Visual Analog Scale, Burden Scale for Family Caregivers short form (BSFC-s), and questions related to satisfaction with the treatment results.

resultsOf 366 patients with available data at 6 months, 118 (32%) died, 82 (22%) achieved mRS 5 (severe disability), 86 (23%) mRS 4 (moderate disability), and 80 (22%) mRS 0-3 (partial to full independence). Survivors reported markedly reduced health status with median EQ-5D-5L Index of 0.3 (IQR 0.1, 0.7) and EQ-VAS of 40 (IQR 20, 70). Caregivers reported scores describing moderate burden, although 45% scored severe to very severe burden (mean ± SD 15.0 ± 6.9). Most caregivers (121/174, 70%) and survivors (44/45, 97.8%) were satisfied with the results of treatment, and 134/174 (77%) caregivers and 40/45 (88.9%) survivors would again consent to the treatment they received. Factors associated with higher EQ-5D-5L included female sex, SAH diagnosis, treatment in Germany (vs. the USA), and absence of elevated intracranial pressure.

conclusionsFor most patients 6 months after severe stroke with respiratory failure and neurocritical care treatment, physical disability and caregiver burden are profound. Nonetheless, most caregivers and nearly all survivors who were able to respond reported satisfaction with treatment and results of critical care including tracheostomy.

Indexed as

Intracerebral hemorrhageIschemic strokeNeurocritical carePatient outcomesQuality of lifeSubarachnoid hemorrhageTracheostomy

Identifiers

PMID42477257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.